Coppell Advisory Solutions LLC Acquires 3,356 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Coppell Advisory Solutions LLC increased its holdings in Vertex Pharmaceuticals by 693.4%, acquiring an additional 3,356 shares, bringing its total to 3,840 shares valued at approximately $1.93 million.
• Vertex Pharmaceuticals reported an EPS of $4.52 for the last quarter, beating estimates, with revenue rising 11.3% year-over-year to reach $2.94 billion.
• Institutional investors hold 90.96% of Vertex Pharmaceuticals' shares, with several recent acquisitions indicating strong interest from the investment community.

Coppell Advisory Solutions LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 693.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,840 shares of the pharmaceutical company's stock after purchasing an additional 3,356 shares during the period. Coppell Advisory Solutions LLC's holdings in Vertex Pharmaceuticals were worth $1,933,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in VRTX. Activest Wealth Management bought a new stake in shares of Vertex Pharmaceuticals during the first quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 45 shares during the last quarter. Mascagni Wealth Management Inc. bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $31,000. Mpwm Advisory Solutions LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $40,000. Finally, Minot DeBlois Advisors LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $44,000. 90.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs purchased 5,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was bought at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the purchase, the director owned 45,000 shares of the company's stock, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Stock Up 2.3%

NASDAQ VRTX traded up $8.82 on Thursday, reaching $397.37. The company had a trading volume of 1,329,815 shares, compared to its average volume of 1,631,277. The stock has a market capitalization of $101.88 billion, a P/E ratio of 28.40 and a beta of 0.44. The company's fifty day moving average is $425.01 and its 200 day moving average is $454.73. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. During the same period last year, the firm posted ($12.83) EPS. The business's revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on VRTX shares. JPMorgan Chase & Co. upped their target price on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an "overweight" rating in a report on Monday, July 14th. Erste Group Bank cut Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. UBS Group set a $553.00 price target on Vertex Pharmaceuticals and gave the company a "buy" rating in a research note on Tuesday, August 5th. Truist Financial set a $490.00 price target on Vertex Pharmaceuticals and gave the company a "buy" rating in a research note on Tuesday, August 5th. Finally, BMO Capital Markets set a $530.00 price target on Vertex Pharmaceuticals and gave the company an "outperform" rating in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $496.05.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.